January 16, 2026

Half Avoid Opioids After Colorectal Surgery

Researchers examine postdischarge pain management after elective colorectal surgery, focusing on how prescribing practices align with actual opioid use at home.

Conexiant

January 15, 2026

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

Conexiant

January 07, 2026

Immunoscore Refines CRC Prognosis, Therapy

Despite a strong evidence base, the assay has not been widely implemented in routine clinical practice.

Conexiant

January 07, 2026

ChatGPT Has Limitations in Clinical Utility for Colorectal Cancer but May Be Useful for Patient Education

A study to be presented at the 2025 ASCO Gastrointestinal Cancers Symposium evaluated the chatbot’s ability to accurately respond to patient inquiries regarding colon cancer by comparing its responses...

The ASCO Post

January 06, 2026

Manta-Shaped Fix for 'Dog Ear' Leaks?

A manta-shaped anastomosis showed no anastomotic leaks in a laparoscopic low anterior resection cohort.

Conexiant

December 22, 2025

AGA strengthens payor ties to ease admin burden

“We view this as an opportunity to work together to alleviate some of these burdens, and I will say that hearing the perspective from payors has been very eye-opening.”

Conexiant

December 11, 2025

GLP-1 drugs pose no cancer risk, review finds

A large systematic review and meta-analysis was limited by a median follow-up of 70 weeks.

Conexiant

May 02, 2024

New NCI Grant to Foster Development of Novel Therapy in Metastatic Colorectal Cancer

The Case Western Reserve University School of Medicine received a 5-year $1.84 million grant to investigate the role of the LRG1 protein in colorectal cancer growth and develop a novel treatment option for patients with metastatic colorectal cancer.

Conexiant

May 02, 2024

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Conexiant